Search

 


700 results found for the [] query

The BARBARA Alliance launches to accelerate dementia clinical trials and unlock new treatments

Date: 17/07/2026

Find out more

Live-cell imaging - Fixation Vs Reality

Date: 15/07/2026

From mitochondrial networks that silently rebalance fusion and fission, to chromosomes that only reveal their fate in the minutes after division, live-cell imaging uncovers dynamics that static snapshots miss entirely. We explore three examples, including how tracking RNA therapeutic vehicles as they transit and escape endosomal compartments in real time resolves ambiguity that even super-resolution imaging of fixed cells can't overcome.

Find out more

ImmunoKey

Date: 08/07/2026

MDC delivers high-quality data with fast turnaround times, clear communication, and a flexible approach to meeting evolving project needs. MDC’s technical expertise, responsiveness, and willingness to adapt have made them a trusted partner, helping us efficiently generate robust data and advance our research with confidence.

Find out more

From Photons to Phenotype

Date: 05/07/2026

By looking beyond the diffraction limit, we have established a method to quantitatively distinguish low-grade breast cancers that appear identical by traditional means. Ultimately, this nanoscale insight could expand access to novel HER2-targeted therapies by reliably identifying low expressing cohorts that would benefit from intervention.

Find out more

The Francis Crick Institute and Medicines Discovery Catapult Open KQ Labs Applications, Accelerating the Next Wave of Data-Driven Health Innovation 

Date: 02/07/2026

Find out more

Medicines Discovery Catapult selects prominent UK life sciences leader,  Professor Sir Mike Ferguson, as its incoming Chair of the Board 

Date: 30/06/2026

Find out more

RNA Therapeutics

Date: 26/06/2026

There is no excerpt because this is a protected post.

Find out more

TRP Targeted Radiopharmaceuticals Summit - San Diego, USA 

Date: 19/06/2026

Visit us at booth 7.

Find out more

Evaluating the cellular tropism of RNA therapeutics ex vivo

Date: 15/06/2026

Lipid nanoparticles (LNPs) are recognised as a leading delivery platform following clinical success in vaccine and therapeutic applications. Medicines Discovery Catapult (MDC) has built a preclinical platform to evaluate LNPs against two major challenges in the field. In this blog, Lead Scientist, Dr Phil Auckland, presents a case study of this workflow using intravenously administered LNPs encapsulating mRNA, which differentially target four major liver cell types.

Find out more

Preclinical evaluation of RNA nanotherapeutics – a case study of lipid nanoparticles

Date: 15/06/2026

Opening new avenues for RNA therapeutics through a preclinical screening and optimisation platform. In this blog, Lead Scientist Dr Phil Auckland describes how applying this platform to a library of 4,500 lipid nanoparticle (LNP) formulations enabled the identification of novel candidates with desirable mechanistic properties and in vivo functionality. Furthermore, we show that integrating multiple in vitro readouts can enhance prediction and thereby improve translation.

Find out more




Medicines Discovery Catapult